These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35254434)

  • 1. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.
    Hussaini SMQ; Gupta A; Anderson KE; Ballreich JM; Nicholas LH; Alexander GC
    JAMA Netw Open; 2022 Mar; 5(3):e221117. PubMed ID: 35254434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.
    Kozlowski S; Birger N; Brereton S; McKean SJ; Wernecke M; Christl L; Kelman JA
    JAMA; 2018 Sep; 320(9):929-931. PubMed ID: 30193265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
    Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA advisers recommend approval of biosimilar filgrastim.
    Traynor K
    Am J Health Syst Pharm; 2015 Feb; 72(4):262, 264. PubMed ID: 25631830
    [No Abstract]   [Full Text] [Related]  

  • 9. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J; Balser S; Windisch J
    Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of Infliximab Biosimilars Among the Medicare Population.
    Chen AJ; Gascue L; Ribero R; Van Nuys K
    JAMA Intern Med; 2020 Sep; 180(9):1255-1256. PubMed ID: 32702080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.
    Qian J
    J Manag Care Spec Pharm; 2021 May; 27(5):660-666. PubMed ID: 33908273
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
    Qureshi ZP; Nagai S; Bennett CL
    JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
    Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
    Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.
    Dean EB; Bond AM
    JAMA Health Forum; 2021 Sep; 2(9):e212634. PubMed ID: 35977178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
    Yazdany J; Dudley RA; Lin GA; Chen R; Tseng CW
    JAMA; 2018 Sep; 320(9):931-933. PubMed ID: 30193264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
    Mouslim MC; Trujillo AJ; Alexander GC; Segal JB
    Value Health; 2020 Dec; 23(12):1599-1605. PubMed ID: 33248515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
    Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
    Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
    Kim SC; Sarpatwari A; Landon JE; Desai RJ
    Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.